In this article we will discuss Durvalumab (Clinical Studies-8). So, let’s get started.
Randomization was stratified by gender, age (< 65 years vs. ≥ 65 years), and smoking history (smoker vs. non-smoker). Patients were randomized 2:1 to receive Durvalumab 10 mg/kg or placebo intravenously every 2 weeks for up to 12 months or until
unacceptable toxicity or confirmed R E C I S T v1.1-defined progression. Assessment of tumor status was performed every 8 weeks.